Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

829 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Six-Month Outcomes in the Long-Term Outcomes After the Multisystem Inflammatory Syndrome in Children Study.
Truong DT, Trachtenberg FL, Hu C, Pearson GD, Friedman K, Sabati AA, Dionne A, Oster ME, Anderson BR, Block J, Bradford TT, Campbell MJ, D'Addese L, Dummer KB, Elias MD, Forsha D, Garuba OD, Hasbani K, Hayes K, Hebson C, Jone PN, Krishnan A, Lang S, McCrindle BW, McHugh KE, Mitchell EC, Morrison T, Muniz JC, Payne RM, Portman MA, Russell MW, Sanil Y, Shakti D, Sharma K, Shea JR, Sykes M, Shekerdemian LS, Szmuszkovicz J, Thacker D, Newburger JW; MUSIC Study Investigators. Truong DT, et al. JAMA Pediatr. 2025 Jan 13. doi: 10.1001/jamapediatrics.2024.5466. Online ahead of print. JAMA Pediatr. 2025. PMID: 39804656
Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma with Main Trunk and/or Contralateral Portal Vein Invasion in IMbrave150.
Finn RS, Galle PR, Ducreux M, Cheng AL, Reilly N, Nicholas A, Hernandez S, Ma N, Merle P, Salem R, Li D, Breder V. Finn RS, et al. Among authors: cheng al. Liver Cancer. 2024 Jun 21;13(6):655-668. doi: 10.1159/000539897. eCollection 2024 Dec. Liver Cancer. 2024. PMID: 39687036 Free PMC article.
APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024.
Lau G, Obi S, Zhou J, Tateishi R, Qin S, Zhao H, Otsuka M, Ogasawara S, George J, Chow PKH, Cai J, Shiina S, Kato N, Yokosuka O, Oura K, Yau T, Chan SL, Kuang M, Ueno Y, Chen M, Cheng AL, Cheng G, Chuang WL, Baatarkhuu O, Bi F, Dan YY, Gani RA, Tanaka A, Jafri W, Jia JD, Kao JH, Hasegawa K, Lau P, Lee JM, Liang J, Liu Z, Lu Y, Pan H, Payawal DA, Rahman S, Seong J, Shen F, Shiha G, Song T, Sun HC, Masaki T, Sirachainan E, Wei L, Yang JM, Sallano JD, Zhang Y, Tanwandee T, Dokmeci A, Zheng SS, Fan J, Fan ST, Sarin SK, Omata M. Lau G, et al. Among authors: cheng al. Hepatol Int. 2024 Dec;18(6):1661-1683. doi: 10.1007/s12072-024-10732-z. Epub 2024 Nov 21. Hepatol Int. 2024. PMID: 39570557
Outcomes of Post-Immunotherapy Durable Responders of Advanced Hepatocellular Carcinoma- with Emphasis on Locoregional Therapy for Oligoprogression.
Liu TH, Chen SC, Rau KM, Lu LC, Lin PT, Su YY, Teng W, Lai SW, Yeh RH, Kao TM, Lee PC, Wu CJ, Chen CH, Hsu CH, Lin SM, Huang YH, Chen LT, Cheng AL, Shen YC; Taiwan Liver Cancer Association Research Group (TRG). Liu TH, et al. Among authors: cheng al. Liver Cancer. 2024 Feb 1;13(5):509-521. doi: 10.1159/000536549. eCollection 2024 Oct. Liver Cancer. 2024. PMID: 39435270 Free PMC article.
An Internet Mantram Repetition Program to Promote Well-being in Breast Cancer Survivors: A Feasibility Randomized Controlled Trial.
Hulett JM, Cheng AL, Bormann JE, Anbari AB, Armer JM, Hartman BM, Ann Bettencourt B, Sherwin LB, Sperling EL, Narkthong N, Reinero C, Rindt H, Schreiber K, Peterson LL, Albright E. Hulett JM, et al. Among authors: cheng al. Integr Cancer Ther. 2024 Jan-Dec;23:15347354241290504. doi: 10.1177/15347354241290504. Integr Cancer Ther. 2024. PMID: 39427264 Free PMC article. Clinical Trial.
829 results